The FDA approved and ADA accepted antimicrobial agent, Atridox, is:

Atridox is recognized as a localized delivery system for doxycycline, specifically a 10% doxycycline gel that is delivered directly into the periodontal pocket using a syringe. This formulation allows for targeted treatment of periodontal disease by ensuring that the antimicrobial agent is concentrated precisely where it is needed, thus enhancing its effectiveness in combating bacteria that contribute to periodontitis.

The delivery method is crucial for achieving therapeutic levels of the medication in the appropriate tissues. This localized approach minimizes systemic exposure and potential side effects while maximizing the direct effect of the antibiotic on the periodontal pathogens.

In contrast, other options do not accurately describe the mechanism of Atridox. For instance, the reference to microspheres or differing concentrations does not align with the approved delivery and formulation of Atridox, which specifically utilizes a gel form. Thus, understanding the formulation and delivery method is key to recognizing the appropriateness of Atridox in clinical application for periodontal treatments.